Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H38O3 |
Molecular Weight | 374.5567 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 5 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(O)=O
InChI
InChIKey=VOGXDRFFBBLZBT-AAQCHOMXSA-N
InChI=1S/C24H38O3/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-27-23(4-2)24(25)26/h5-6,8-9,11-12,14-15,17-18,23H,3-4,7,10,13,16,19-22H2,1-2H3,(H,25,26)/b6-5-,9-8-,12-11-,15-14-,18-17-
Molecular Formula | C24H38O3 |
Molecular Weight | 374.5567 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 5 |
Optical Activity | ( + / - ) |
Icosabutate (also known as PRC-4016 or NST-4016), a cholesterol ester transfer protein inhibitor was developed by NorthSea Therapeutics for the treatment of combined dyslipidemias and hypertriglyceridemia. Icosabutate successfully completed phase II clinical trial for hypertriglyceridemic subjects, where was studied the drug efficacy and safety. In April 2018 NorthSea Therapeutics announced that its lead product, icosabutate would be further developed as an effective and safe therapeutic approach to treating both non-alcoholic steatohepatitis and its associated comorbidities.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26892135
After a 6-8 week run-in period, men and women with TG levels ≥ 500 mg/dL and ≤ 1500 mg/dL were randomized to double-blind treatment with placebo or icosabutate 600 mg for 12 weeks
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:30:21 GMT 2023
by
admin
on
Sat Dec 16 09:30:21 GMT 2023
|
Record UNII |
562599X5JL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12990
Created by
admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
|
PRIMARY | |||
|
CD-89
Created by
admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
|
PRIMARY | |||
|
C166820
Created by
admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
|
PRIMARY | |||
|
562599X5JL
Created by
admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL3707220
Created by
admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
|
PRIMARY | |||
|
9888
Created by
admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
|
PRIMARY | |||
|
78210211
Created by
admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
|
PRIMARY | |||
|
100000180107
Created by
admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
|
PRIMARY | |||
|
1253909-57-7
Created by
admin on Sat Dec 16 09:30:21 GMT 2023 , Edited by admin on Sat Dec 16 09:30:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
PARENT -> DERIVATIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|